Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously ...

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at merck.com →

◆ Verified

Fusion42 · 26 September 2026 · Fusion42 review

Daiichi Sankyo and Merck have voluntarily withdrawn their biologics license application to the FDA for accelerated approval of ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer due to insufficient supportive data. Patient enrolment continues in ongoing Phase 3 trials evaluating its efficacy in ES-SCLC and other cancers.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face stricter FDA standards for accelerated approval which have halted ifinatamab deruxtecan's US launch. Shift focus now to upcoming Phase 3 trial results as your gateway to US market access.

◆ Coverage

1 source · 25 Sep 2026

◆ Related on Wire

◆ Topics

Biotechregulatory-withdrawaloncologyclinical-trialsdrug-approvalFDA